Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025 Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026 ZUG, Switzerland, July 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), updated...

Rapidly Progressing With RAPIDe-3 -- Readout Pulls Forward

Aalberts Proposed acquisition of GVT for c. € 213m

The proposed acquisition of Grand Venture Technology will strengthen Aalberts position in APAC. Despite current challenges in key end markets (Automotive, Construction and Machine Building), Aalberts continues to execute on operational improvements, which lay the groundwork for a robust earnings leverage upon revenue recovery. We maintain our Accumulate rating on valuation grounds.

Morning Notes : AALB NA, IVEVF FP, WPHB BB

: AALB NA, IVEVF FP, WPHB BB